Introduction
A previous review describes the current concept of pneumococcal meningitis in cochlear implant recipients based on recent laboratory studies. It examines possible routes of spread of S. pneumoniae infection to the meninges in cochlear implant recipients. It also provides insights into fundamental questions concerning the pathophysiology of pneumococcal meningitis in implant recipients. This review is the second part of a series and it examines methods to minimize the risk of post cochlear implant meningitis based on the current clinical data and the most recent scientific laboratory evidence.
Implant design and inner ear trauma and infection
Children receiving an implant with a positioner had 4.5 times the risk of developing meningitis compared to those who had other cochlear implant types 
Fibrous tissue seal
The integrity of the fibrous tissue seal around the electrode array at the cochleostomy site has been considered to be very important in preventing infection spread from the middle ear to the inner ear and thence to the CNS Animal studies have demonstrated that a two week old fibrous seal around the implant was mature enough to prevent horseradish peroxidase from entering the inner ear from the middle earn 18 • Nevertheless, the appearance of inflammatory cells and bacteria within the fibrous seal around the electrode array suggested that the fibrous seal, which macro and microscopically appeared mature at four weeks, was not entirely effective in preventing bacteria from entering the inner ear from the middle ear . .
. be a better sealing material than autogenous fascia.
Attempts have been made to osseointegrate the electrode array within the cochleostomy to seal the potential gap between the electrode and the cochleostomy site. Although Purser and colleagues 16 were unable to achieve osseointegration with their titanium sealing device, the fibrous tissue generated within the gap between the titanium device and the edge of cochleostomy was sufficient to resist the transgression of bacteria from middle to inner ear. The problem with osseointegration of the electrode array at the entry site to the inner ear is the potential difficulty it creates for future re-implantation. This is an important issue as there are more deaf children and infants receiving cochlear implants, the device will undergo technological improvement throughout the subject's life span.
Other preventative strategies
In addition to atraumatic surgical technique and cochlear implant design and an adequate and robust periimplant seal, the FDA has recommended immunisation against S. pneumoniae for implant recipients in the hope that this will reduce the incidence of pneumococcal meningitis It is important to appreciate that there are more than 90 serotypes of S. pneumoniae and the maximum number ofserotypes covered by the currently available vaccines is 23. Whether implant recipients acquired meningitis from non-vaccine covered serotypes remains to be determined. There is also a concern that the incidence of meningitis caused by non-vaccine covered serotypes may increase with the universal use of pneumococcal vaccine 41 • This concern was raised because the use of PCV7 has been shown to increase the frequency of acute otitis media caused by non-vaccine covered serotypes In addition to pneumococcal vaccination, another preventive strategy was examined. Antibiotic coating of the electrode array with a ciprofloxacin!Healon® mixture was shown to reduce the risk of pneumococcal meningitis when the bacteria were given via the haematogenous route 45 • This protective effect was observed at 4 weeks after implantation. However, when the bacteria were given via the middle or the inner ear, the risk reduction was not statistically significant. The results suggested that the use of an antibiotic coated electrode array may have a role in preventing future cases of meningitis in human subjects. Further research in this field is required especially there is a concern of development of antimicrobial resistant strains of the bacteria from the extensive use of antimicrobial agents.
Conclusion:
An increase in the number of reported cases of implant-related meningitis has prompted action to evaluate implant designs and surgical techniques in order to reduce the risk of meningitis among cochlear implant subjects. An atraumatic insertion ofthe electrode array will prevent the creation of a more direct communication between the inner ear and subarachnoid space.
An intact seal around the cochlear implant is important to prevent the direct spread of infection from the middle ear to the inner ear and the meninges. The quality and the nature of the seal are important factors to consider in the prevention ofimplant related infections, and should take the nature of immune surveillance into account. The type and configuration of the prosthetic material used in cochlear implants also contribute to the biological safety in patients with cochlear implants. This is illustrated by a higher risk of meningitis associated with implants with a positioner and a higher risk of inner ear infection when Dacron is used as a peri-impant seal. The use of pneumococcal vaccination appeared to be very effective in preventing meningitis in implanted animals when the bacteria were inoculated via the haematogenous or the middle ear route. This finding supports the current FDA recommendation and all implant recipients should be given age appropriate vaccine.
Many ofthe lessons associated with cochlear implantation will be common to other implantable devices associated with the CNS and importantly recent studies examining this issue will lead to even safer application of the cochlear implant and other CNS associated devices.
